Lisa La on the Design of a Study Evaluating Diabetes in Patients with Multiple Myeloma
The director of clinical research in the Center for Cancer Care at White Plains Hospital explained the design of the study which evaluated diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.
A descriptive analysis of the CONNECT Multiple Myeloma Registry, presented at the 2020 ASH Annual Meeting & Exposition, aimed to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in diabetic versus nondiabetic patients enrolled in the registry.
In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, explained the design of the study.
Transcription:
Sure, so the Celgene, it’s actually a Celgene observational study. It's a large multicenter prospective observational study, primarily enrolling newly diagnosed multiple myeloma patients. So, the sample size that they've enrolled from 2009 to 2016, was about 3011 newly diagnosed myeloma patients across 250 sites. Those sites are community, academic, and government sites across the entire US. And it's pretty accurate in terms of not focusing on certain regions of the US, but across all of the entire… so I would say it's pretty representative of the general population. So, patients that were eligible, just as long as you were 18 years and older and had some sort of diagnosis of myeloma, and less than 2 months before you enrolled, so they are they're just being pretty much followed up for treatment and outcomes.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
